[Investigations on the clinical effect of the antirheumatic agent piroxicam (author's transl)].
In the glucocorticoid-sparing test, which shows certain advantages compared with other experimental procedures, the clinical efficacy of the new antirheumatic substance piroxicam (Feldene) was investigated. It was shown that a single daily dose of 20 mg piroxicam gave at least an equal, if not better, effect compared with other substances tested earlier, as far as comparison is permissible between two collectives treated with different substance. The mean saving of prednisone was 5.7 mg/day and according to another evaluation 64.7% of the previously required dose of prednisolone. It is worth noting that owing to the long half-life there is a remarkable clinical effect over at least 24 hours with a single daily dose. Tolerance was good. Pathological laboratory values which were definitely to be attributed to the preparation were not seen in a trial period of a maximum of four weeks.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D010894:Piroxicam; D011239:Prednisolone / Q000627:therapeutic use; D011725:Pyridines; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013843:Thiazines
D000893:Anti-Inflammatory Agents; D011725:Pyridines; D013843:Thiazines; D010894:Piroxicam; D011239:Prednisolone
Klinische Wirkung des Antirheumatikums Piroxicam.